Every year Omikron Italia invests about 15% of its turnover in Research and Development on projects carried out in collaboration with the most prestigious Italian and foreign Institutes.
The Main Fields of Research are the following:
- Glaucoma and other Neurodegenerative Ophthalmic diseases
- Diabetic Retinopathy
- Experimental studies on vascular contractility and permeability
- Hemorrhoidal Disease
Discover more
The Main Fields of Research
Glaucoma and other Neurodegenerative Ophthalmic deaseases
- The first controlled clinical study versus placebo which evaluated the effect of a medical treatment on the quality of life in glaucomatous patients was concluded and published in an International Journal. In particular, this clinical study international, multicenter, randomized, placebo controlled, crossover trial evaluated the effect of citicoline in oral solution on quality of life in patients with glaucoma.
- An in vitro study which demonstrated that in a 3D glaucoma model the topical treatment with citicoline Eye drops protects trabecular meshwork cells from oxidative stress injuries was concluded and published in an International Journal.
- A multicenter Randomized Clinical Trial (RCT) with citicoline in ophthalmic solution in glaucomatous patients with progression damage was concluded and published in an International Journal; this Trial has been performed by Italian University Institutes and provided morphological and functional evaluations.
- A Clinical Trial, carried out by an Italian Research Institute, with citicoline in oral solution in the treatment of patients with neurodegenerative diseases involving the optic nerve was concluded and published in an International Journal.
- An ocular kinetics study in human performed with citicoline in ophthalmic solution in patients undergoing vitrectomy was concluded and published in an International Journal
- A Clinical Study carried out by an Italian Research Institute with liposomal citicoline in eye drops in the treatment of glaucomatous patients was concluded and published in an International Journal.
- A Clinical Trial performed by an Italian Research Institute with citicoline in ophthalmic solution in the treatment of glaucomatous patients was ended and published in an International Journal.
- The first multicenter Trial with citicoline in oral solution, never carried out before on the progression of the campimetric damage in glaucomatous patients has been performed and was published in an International Journal.
- The preclinical and clinical development of OMK1®, citicoline and hyaluronic acid in ophthalmic solution (Medical Device CE), of OMK2®, citicoline, hyaluronic acid and vitamin B12 in ophthalmic solution (Medical Device CE) and of OMK1®-LF citicoline and hyaluronic acid in liposomal ophthalmic solution without preservatives (Medical Device CE) was carried out in Italy.
Diabetic Retinopathy
- A Clinical Trial, performed by an Italian University Institute, on corneal morphology and functionality in patients with advanced stage diabetic neuropathy treated with citicoline and Vit B12 in eye drops was concluded and published in International Journal.
- A Clinical Trial, performed by an Italian Research Institute, in patients with incipient Diabetic Retinopathy treated with citicoline and Vit B12 eye drops was concluded and published in International Journal.
- An Experimental Trial on animals with induced Diabetic Retinopathy in treatment with liposomal citicoline in eye drops, performed by a Spanish University Institute, was concluded and published in International Journal.
- An Experimental Trial on animals with induced Diabetic Retinopathy in treatment with citicoline and Vit B12 in eye drops, performed by an Italian University Institute, was concluded and published in International Journal.
- An Experimental Trial, performed by the National Health Institute (Istituto Superiore di Sanità), in vitro on retinal cell cultures and in vivo with rats to evaluate the neuroprotective effect of treatment with citicoline and Vit B12 in eye drops on the possible structural and functional alterations of the retinal neuroglial component in the diabetic disease was concluded and published in an International Journal.
Experimental studies on vascular contractility and permeability
Hemorrhoidal Disease
- A Clinical Study, performed by an Italian University Institute, to evaluate the efficacy of CONAN® proctological cream (Medical Device CE) in patients with hemorrhoidal disease, anal fissures and anitis was concluded and published in an International Journal.
- A multicenter, prospective, randomized, controlled, triple-blind Clinical study, performed independently by the Italian Society of Colo-Rectal Surgery (SICCR) to evaluate the efficacy of a mixture of flavonoids in the treatment of acute hemorrhoidal disease was concluded and published in an International Journal.
- The preclinical and clinical development of a new formulation for topical use in the treatment of hemorrhoids, CONAN® proctological cream (Medical Device CE) was performed.
| THERAPEUTIC AREA | PHARMACEUTICAL FORM | EXPECTED LAUNCH |
|---|---|---|
| Ophthalmology/Glaucoma | eye-drops | 2026 |
| Vascular disease (Antithrombotic) | solution for injection | 2024 |
Patent Application: PCT/IB2011/050663
Title document: TOPICAL CITICOLINE FOR THE TREATMENT OF GLAUCOMA
| APPLICATION NUMBER | PUBLICATION | STATUS | TITLE DOCUMENT HOLDER (PATENT HOLDER) | |
|---|---|---|---|---|
| PCT | WO2011101802 | 25/08/2011 | OMIKRON ITALIA | |
| NATIONAL STAGE | EUROPE EP2538918 |
02/01/2013 | GRANT OF PATENT IS INTENDED 06/06/2014 |
OMIKRON ITALIA |
| NATIONAL STAGE | USA US8822429 |
13/12/2012 | GRANT OF PATENT IS INTENDED 13/08/2014 |
OMIKRON ITALIA |
| NATIONAL STAGE | JAPAN JP5801324 |
04/09/2015 | GRANT OF PATENT IS INTENDED 18/08/2015 |
OMIKRON ITALIA |
Patent Application: PCT/IB2017/056400
Title document: OPHTHALMIC FORMULATION COMPRISING CITICOLINE CARRIED BY LIPOSOME FOR THE TREATMENT OF GLAUCOMA
| APPLICATION NUMBER | PUBLICATION | STATUS | TITLE DOCUMENT HOLDER (PATENT HOLDER) |
|
|---|---|---|---|---|
| PCT | WO2018073720 | 26/04/2018 | ||
| NATIONAL STAGE | USA US 10576039 |
16/04/2019 | GRANT OF PATENT IS INTENDED 03/03/2020 |
OMIKRON ITALIA |
| ABIOGEN PHARMA Pisa – Italy |
Glibenclamide + Meformin Hydrocloride (Diaglimet ®) RRR-α-tochoperol (Armilla ®) |
| URSAPHARM Arzneimittel GmbH Germany |
Retinol Palmitate (VitA-POS) |
Thanks to licensing agreements with foreign major pharmaceutical companies, since 2013 Omikron Italia started an important internationalization process that is more and more consolidating and increasing over the years.
Some Omikron Italia medicinal products, medical devices and nutraceuticals are already marketed in several European Countries and Extra European Countries. Moreover, registrations in 3 different continents are currently ongoing.
The continuous innovation of proposed therapeutic approaches together with an increasing attention to the quality of the products, to the interest towards the therapeutic needs of patients and to the constant efforts in Research allowed Omikron Italia to steadily expand over the years in many Countries.
Partnership Map
Partnership Map
Countries with direct presence
Countries with indirect presence (marketing of Omikron Italia products through business partner)
Countries with indirect presence (marketing agreements about Omikron Italia products with registration process ongoing)
Research Award A.I.S.G. – Omikron Italia 2023 “Marco Centofanti” su: Neuroprotezione e Glaucoma
Omikron Italia, a leading company in the ophthalmic sector, intends to actively contribute to the development of research in Italy through funding for 2 young researchers active in the physiopathological and / or clinical field relating to Neuroprotection in Glaucoma.
Read and download the complete announcement, fill in the fields indicated and send your Curriculum Vitae together with the full text of the publications of Research Projects previously conducted in the aforementioned area to the e-mail addresses dir.amministrativa@omikronitalia.it and oftalmologicaaisg@libero.it by December 31, 2022.
Get involved
